Carlsmed Q2 2026 Earnings: 57% Revenue Growth Comes With Wider Losses

Carlsmed’s Q2 2026 revenue rose 57% year over year to $18.9 million as aprevo procedure volumes and trained-surgeon adoption increased. Gross margin expanded, but faster growth in research, sales, and administrative spending pushed the GAAP net loss to $10.5 million from $6.8 million. Carlsmed raised full-year 2026 revenue guidance to $74 million–$78 million. Key follow-up issues include expense discipline, the decline in liquid resources, cervical commercialization, and execution around enhanced Medicare reimbursement for inpatient aprevo lumbar procedures beginning in October 2026.